Literature DB >> 34312131

CDK4/6 inhibitor-induced colitis: a case report and review of the literature.

Azhar Abbas Malik1, Haider Abbas2, Zin Mar Oo2, Zerlene Lim2.   

Abstract

A 72-year-old woman with metastatic ER/PR-positive breast cancer who had been on ribociclib and letrozole for 1 year developed severe life-threatening colitis. She presented to emergency department with features of acute abdomen and diarrhoea. The diagnosis of colitis was confirmed radiologically as well as by histopathological examination of the biopsy specimen and the patient clinically improved after withholding ribociclib and receiving corticosteroids compatible with ribociclib-induced colitis. The mechanism of injury in CDK 4/6 inhibitor-induced colitis is unknown but may be related to recruitment of inflammatory cells. Whether the development of colitis is associated with tumour response is an interesting and unanswered question. © BMJ Publishing Group Limited 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Breast cancer; Unwanted effects / adverse reactions

Mesh:

Substances:

Year:  2021        PMID: 34312131      PMCID: PMC8314699          DOI: 10.1136/bcr-2021-242766

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  1 in total

1.  FAM117A Is a New Prognostic Marker of Lung Adenocarcinoma and Predicts Sensitivity to PD0332991.

Authors:  Chao Wu; Jiajin Zhang; Kuan Wang; Mengjiao Fan; Yi Hu
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-03       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.